Dronabinol Capsule
Product Images NDC 0527-4125

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Dronabinol (NDC 0527-4125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lannett Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2.5 mg (2.5 mg 60s)

This is a description of Dronabinol Capsules, a drug manufactured by Ascent Pharmaceuticals Inc. and distributed by Lannett Company Inc. The drug comes in a 60 capsule bottle and each capsule contains 2.5mg of Dronabinol. The recommended dosage is available in the package insert. The drug should be stored in a well-closed container and kept in a cool environment between 2 to 8 degrees Celsius. The packaging warns against accepting the drug if the bottle opening is broken or missing.*

FDA Label Image

Abs (Dronabinol Absorption)

This is a summary of the pharmacokinetic parameters of Dronabinol in healthy subjects under fasted conditions. The study involved 34 subjects between 20-45 years. The table shows mean (SD) PK Parameter Values for twice-daily doses of 25mg, 5mg, and 10mg. The parameters include Cpnax (maximum observed plasma concentration), Ty (time to maximum observed plasma concentration), and AUC.1y (area under the plasma concentration-time curve from 0 to 12 hours).*

FDA Label Image

Fig1 (Dronabinol Figure1)

The text represents a graph showing the mean appetite change from baseline for two drugs: Dronabinol (at a dose of 2.5 mg BID) and Placebo. The data is shown for several weeks. The graph also indicates that there is a significant statistical difference between the two drugs (p-value<0.05).*

FDA Label Image

Rc (Dronabinol Rc)

This appears to be a list of symptoms related to mental and physical conditions. The symptoms include dizziness, abnormal thoughts, euphoria, stomach pain, nausea, paranoid reactions, sleepiness, and vomiting. It is not clear what specific condition these symptoms are related to, but they could potentially be related to a range of mental health or physical health issues. Further evaluation by a healthcare provider may be necessary for a proper diagnosis and treatment plan.*

FDA Label Image

Struct (Dronabinol Struct)

FDA Label Image

Adr (Dronabinol Adv)

This is a description of common and less common adverse reactions reported during clinical trials of an unknown drug. The common adverse reactions include symptoms such as asthenia, palpitations, tachycardia, and abdominal pain, among others. The less common adverse reactions include symptoms such as chills, hypotension, anorexia, hepatic enzyme elevation, depression, nightmares, and vision difficulties, among others. The incidence of these adverse reactions ranges from greater than 1% to less than or equal to 1%.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.